For instance, efalizumab, a humanized mAb against LFA-1, has shown some efficacy in the preclinical study and early stage of clinical trials for psoriasis treatment, but it has been halted because of the risk of progressive multifocal leukoencephalopathy. This evidence concerns the gene ITGB2 and progressive multifocal leukoencephalopathy.